ITF 3756
Alternative Names: ITF-3756Latest Information Update: 24 Jun 2022
Price :
$50 *
At a glance
- Originator Italfarmaco
- Class Antineoplastics; Antivirals
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; COVID 2019 infections
Most Recent Events
- 29 May 2022 ITF 3756 is available for licensing as of 29 May 2022. https://www.italfarmaco.com/en-us/Activities/Business-development
- 03 May 2022 Preclinical trials in COVID-2019 infections in Italy (unspecified route) as of April 2022
- 03 May 2022 Pharmacodynamics data form a preclinical study in COVID-2019 infections released by Italfarmaco